SAMPRE NUTRITIONS LTD.

Sampre Nutritions Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI regulations and the company's code of conduct, specifically for the announcement of unaudited standalone and consolidated financial results for the first quarter of the financial year 2026-27, ending on June 30, 2026. The trading window will remain shut from July 1, 2026, until 48 hours after the declaration of these financial results. The exact date of the Board of Directors' meeting to approve these results will be communicated later. Promoters, directors, designated persons, and their immediate relatives are prohibited from trading during this period.

Sampre Nutritions Ltd. has issued a commemorative communication acknowledging approximately 30 years of business association with a customer entity. This disclosure, made under Regulation 30 of the SEBI (LODR) Regulations, 2015, is intended for transparency and dissemination of information to stakeholders. The company clarifies that this does not relate to any new contract, order, agreement, or strategic partnership, nor does it involve any financial commitment or modification of existing commercial terms. The disclosure is voluntary and should not be construed as an advertisement or endorsement.

Sampre Nutritions Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.

Sampre Nutritions Ltd has announced the closure of the trading window for the fourth quarter and financial year 2025-26. The closure will commence on 1 April 2026 and will last until 48 hours after the declaration of audited financial results. The decision is in accordance with Regulation 9 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the Company’s Code of Conduct. Promoters, directors, designated persons, specific connected persons, and their immediate relatives are advised not to trade in securities of the Company during this period.

Sampre Nutritions Ltd has submitted a clarification regarding information circulating on certain social media platforms alleging a combined deal with Reliance, Tolaram and Rama Exports. The company has confirmed that it has independently executed separate agreements with each of these entities. Any revenue projections or figures circulating on social media platforms are speculative and not endorsed by the company. Sampre Nutritions is not associated with the said Telegram channels and is examining appropriate steps in this regard. The company has reviewed the trading data and based on the information presently available, there is no material information that warrants further disclosure.

Sampre Nutritions Ltd has appointed Pradeep Narendra Poddar as a non-executive non-independent additional director, subject to shareholder approval. The appointment is in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosures) Requirements, 2015. The Board also approved the standalone and consolidated unaudited financial results for the third quarter and nine-month period ended 31 December 2025.

Sampre Nutritions Ltd, a company listed on the BSE with the scrip code SAMPRE: 530617, held a board meeting on 13 February 2026. The board appointed Pradeep Narendra Poddar as a non-executive non-independent additional director, subject to shareholder approval. The board also approved the standalone and consolidated unaudited financial results for the third quarter and nine-month period ended 31 December 2025. The financial results are enclosed in Annexure A, accompanied by the limited review reports issued by the statutory auditors of the Company.

Sampre Nutritions Ltd has scheduled a Board of Directors meeting on 13th February 2026 to consider and approve the unaudited standalone and consolidated financial results for the third quarter and nine-month period ended 31st December 2025. Additionally, the Company will appoint a new non-executive non-independent additional director on the Board.

Sampre Nutrition Holdings Limited, a wholly owned subsidiary of Sampre Nutritions Limited, has entered into a Land Purchase and Allocation Agreement with Orascom Industrial Parks, a company incorporated under the laws of the Arab Republic of Egypt. The purpose of the agreement is to acquire an industrial land parcel for the establishment of food processing and confectionery manufacturing plants and facilities. The agreement does not involve any shareholding or related party transactions. Sampre Nutrition Holding Limited is a wholly-owned subsidiary of Sampre Nutritions Limited.

The Chairman and MD of Sampre Nutritions Ltd, Brahma Gurbani, has been featured in a business magazine's leadership and industry perspectives edition. This disclosure is made in the interest of transparency and good corporate governance. The magazine feature highlights Gurbani's vision, discipline, and enterprise that have elevated the Indian confectionery industry globally. It also emphasizes how long-term commitment builds institutions and purpose-led leadership creates enterprises that endure.